When the liver hardens the heart: Valvular calcification as an emerging cardiohepatic phenotype in cirrhosis

Abstract

Although valvular calcification is still a little-known aspect of cardiohepatic interactions, cardiovascular disease has become a significant predictor of outcomes in patients with liver cirrhosis. Some studies present significant evidence that cirrhosis of any cause strongly predicts mitral annular calcification, while cirrhosis, especially of fatty aetiology, is independently associated with aortic valve calcification. These correlations show a clear liver-driven pro-calcific phenotype, even though cirrhotic patients have a lower burden of conventional cardiovascular risk factors than matched cardiovascular controls. Researchers advance the field from descriptive associations to clinically meaningful risk stratification by combining robust multivariable modelling with pragmatic echocardiographic calcium scoring. Their results highlight the need for integrated hepatology–cardiology approaches and challenge conventional views of cardiovascular risk in cirrhosis. It is important to acknowledge valve calcification as a structural sign of systemic liver disease, which may have consequences for long-term cardiovascular care, transplant evaluation, and surveillance.

Key Words: Cirrhosis; Cardiohepatic interaction; Valvular calcification; Metabolic dysfunction; Fatty liver; Risk stratification

Core Tip: One new but little-known aspect of cardiohepatic disease is valve calcification. Cirrhosis of any aetiology strongly predicts mitral annular calcification, even in the presence of fewer conventional cardiovascular risk factors, whereas fatty liver-related cirrhosis is independently linked to aortic valve calcification. These results imply that a unique pro-calcific cardiovascular phenotype caused by hepatic and metabolic dysfunction is promoted by cirrhosis. Regular evaluation of cirrhosis and transplants should include echocardiographic assessment of valvular calcification to enhance cardiovascular risk stratification and facilitate early, multidisciplinary intervention.

INTRODUCTION

Clinicians have struggled with a confusing cardiovascular paradox in liver cirrhosis (LC) for decades. Patients with advanced liver disease have considerably higher cardiovascular mortality despite generally favourable traditional risk factor profiles, such as lower blood pressure, lower cholesterol, and attenuated atherosclerosis[1-3]. The idea that cirrhosis is a somewhat “cardioprotective” metabolic state has been maintained by this contradiction, despite growing scepticism. This oversimplified perspective is disproved by the seminal study[1] comparing valvular calcification in LC vs non-cirrhotic controls, which offers strong evidence that shifts our attention to ectopic calcification as a crucial, hitherto overlooked pathway influencing cardiovascular risk in this susceptible group.

In addition to electrophysiological alterations and the prolongation of the QT interval in cases of cirrhotic cardiomyopathy, chronic liver diseases can cause systolic and diastolic dysfunctions, all of which may fully improve following liver transplantation[4,5]. Patients with non-alcoholic fatty liver disease (NAFLD), hepatitis C, and primary biliary cirrhosis have shown cardiac abnormalities. Conversely, both acute and chronic heart failure can result in acute hepatic injury and chronic congestive hepatopathy with liver failure symptoms and laboratory results specific to either congestive hepatopathy or ischaemic hepatitis. Good cardiac and hepatic evaluation is necessary because certain systemic diseases impact both the liver and the heart[6]. For improved diagnosis, treatment, and prognosis in these patient categories, hepatologists and cardiologists must work together[7].

Although portal hypertension and hepatic decompensation have historically been the main perspectives on LC, increased survival has drawn attention to extrahepatic complications, especially cardiovascular disease. Beyond the well-established notion of cirrhotic cardiomyopathy, mounting data suggests that cirrhosis encourages myocardial and systemic vascular remodelling, which has significant prognostic ramifications[8,9]. In order to better reflect metabolic aetiology, increase diagnostic precision, and lessen stigma, the term NAFLD has changed to metabolic dysfunction-associated fatty liver disease (MAFLD)[10] and, more recently, metabolic dysfunction-associated steatotic liver disease, placing more emphasis on cardiometabolic drivers than exclusion criteria[11].

Patients with cirrhosis, particularly those MAFLD, now have cardiovascular disease as their primary nonhepatic cause of death[12,13]. However, within the cardiohepatic spectrum, structural cardiac manifestations like valvular calcification have not received enough attention[14].

VALVULAR CALCIFICATION: MORE THAN AN INCIDENTAL ECHOCARDIOGRAPHIC FINDING

It is becoming more widely acknowledged that mitral annular calcification (MAC) and calcific aortic valve disease are active, controlled processes rather than passive degenerative phenomena[15,16]. Adverse cardiovascular outcomes, such as heart failure, arrhythmias, stroke, and mortality, are linked to both conditions. Atherosclerosis and valvular calcification share risk factors in the general population, including obesity, diabetes, ageing, and chronic kidney disease. There is a significant knowledge gap in the treatment of hepatology-cardiology overlap because it is unclear whether cirrhosis contributes to valvular calcification on its own, independent of conventional cardiovascular risk factors. Several strong confounders for valvular calcification including age, chronic kidney disease, disturbances of mineral metabolism, systemic inflammation, and overall metabolic risk burden are well-known contributors to valvular calcification and should be considered. Because renal dysfunction and altered calcium-phosphate homeostasis are relatively common in cirrhosis, the observed calcification may represents a truly liver-specific effect or it reflects the broader CKD and inflammatory burden frequently associated with advanced liver disease[17,18].

Vuckovic and colleagues present a meticulously planned comparison of valvular calcification in LC patients vs age- and sex-matched cardiovascular controls. The authors separate calcific burden as a structural marker rather than a result of advanced valve dysfunction by excluding patients with haemodynamically significant valvular disease and using standardised echocardiographic calcium scoring. Previously dominated by heterogeneous or registry-based studies, this approach enables a nuanced assessment of cirrhosis-specific effects on valvular remodelling[1]. Since clear causation has not yet been shown, these findings are still purely hypothetical.

DIVERGENT CALCIFICATION PATTERNS: AORTIC VALVE VERSUS MITRAL ANNULUS

One of the most striking observations is the divergent pattern of valvular involvement. Fatty liver–related cirrhosis was independently associated with aortic valve calcification (AVC), whereas cirrhosis of any etiology strongly predicted MAC. This distinction is clinically meaningful, as AVC and MAC differ in their pathophysiology, hemodynamic consequences, and prognostic implications[19,20]. The finding that AVC clustered specifically with metabolic cirrhosis supports the concept of a metabolically driven fibro-osteogenic process affecting the aortic valve, while MAC appears to represent a broader structural consequence of chronic liver disease[21]. Notably, compared to cardiovascular controls, patients with cirrhosis in this study had a similar or higher calcific burden but a lower prevalence of traditional cardiovascular risk factors, such as hypertension, hyperlipidaemia, and prior myocardial infarction. The long-held belief that cirrhosis protects against calcific cardiovascular disease because of hypotension or changed lipid profiles is called into question by this paradox. Rather, it supports the notion that cardiovascular remodelling in cirrhosis is driven by liver-specific mechanisms rather than just traditional risk factors[22,23].

MECHANISTIC LINKS BETWEEN CIRRHOSIS AND VALVULAR CALCIFICATION

A web of interrelated systemic and molecular pathways explains the reported correlations between cirrhosis and valvular calcification. The production of pro-inflammatory cytokines, reactive oxygen species, and profibrotic mediators that support osteogenic reprogramming of valvular interstitial cells is facilitated by chronic systemic inflammation and prolonged oxidative stress, two key characteristics of advanced liver disease[24,25]. Nitric oxide bioavailability and vascular homeostasis are compromised by concurrent insulin resistance and endothelial dysfunction, which promotes extracellular matrix remodelling and mineral deposition in valvular tissue. Lipotoxicity, adipokine imbalance, and abnormal calcium-phosphate and vitamin D signalling all contribute to the acceleration of pro-calcific signalling pathways, such as Runx2 and BMP activation, in metabolic cirrhosis[26,27]. New research also links changed systemic iron management and ferroptosis, an iron-dependent kind of controlled cell death, to hepatic fibrogenesis and cardiovascular calcification. Therefore, it is possible that lipid peroxidation, mitochondrial dysfunction, and disruption of the glutathione system are common cardiohepatic molecular factors that connect the development of fibrosis to valvular mineralisation[28-30]. More research is needed to support these proposed mechanisms (Figure 1).

Figure 1 Mechanistic pathways linking liver cirrhosis to valvular calcification. Liver cirrhosis promotes valvular calcification through interconnected inflammatory, metabolic, vascular, and iron-dependent pathways that converge on osteogenic differentiation of valvular interstitial cells (VICs). These processes collectively drive VIC trans differentiation toward an osteoblast-like phenotype, culminating in progressive aortic and mitral valve calcification. ROS: Reactive oxygen species; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha.

ECHOCARDIOGRAPHIC CALCIUM SCORING: A PRAGMATIC CLINICAL TOOL

Echocardiographic calcium scoring provides a practical, radiation-free alternative that is especially appealing in cirrhosis and transplant populations, even though computed tomography is still the gold standard for calcium quantification[31-33]. It has been demonstrated that the semiquantitative method employed by Vuckovic et al[1] correlates with computed tomography-derived calcium scores and offers incremental prognostic information. However, the echocardiography calcium scoring model requires external validation. Crucially, routine cirrhosis care already incorporates echocardiography, allowing for quick clinical translation without adding to the expense or burden on patients[34,35].

FROM ASSOCIATION TO RISK STRATIFICATION

The study’s strong multivariable modelling is one of its main advantages[1]. Strong discrimination and calibration for both AVC and MAC prediction models are demonstrated by the authors, indicating possible use for cardiovascular risk stratification in cirrhosis clinics. These results establish the foundation for incorporating structural cardiac markers into standard hepatology workflows, especially for liver transplant evaluation where cardiovascular risk assessment is crucial, even though external validation is necessary[36,37].

This evidence has a clear practical translation. The typical pre-transplant cardiovascular evaluation, which frequently concentrates on coronary artery disease and systolic function, is now clearly insufficient for hepatologists and transplant doctors. After further validation, a low-cost, low-risk, and high-yield addition to the evaluation protocol is the use of semi-quantitative echocardiographic calcium scoring of the mitral annulus and aortic valve. Finding substantial valvular calcification, particularly MAC, may improve peri-operative risk assessment and direct the escalation of medical care[38,39]. On the other hand, cardiologists should actively look for advanced liver fibrosis when they find significant MAC or early, disproportionate AVC, especially in a patient with metabolic risk factors[40,41]. This connection is all too frequently overlooked. A more comprehensive diagnostic loop is produced by this two-way screening.

THERAPEUTIC AND PREVENTIVE IMPLICATIONS

There are significant therapeutic ramifications when valvular calcification is identified as a component of the cardiohepatic syndrome. Both hepatic and cardiovascular benefits may result from aggressive management of metabolic risk factors, cautious blood pressure optimisation, and consideration of renin-angiotensin-aldosterone system inhibition. Targeting systemic inflammation and metabolic dysfunction in cirrhosis may represent a logical upstream strategy deserving of prospective evaluation, even though no therapy has conclusively stopped the progression of valvular calcification[42,43].

Implications for public health

This study is conducted in the midst of a global epidemic of MAFLD, which is expected to overtake all other causes of cirrhosis and liver transplantation. The existence of cardiovascular symptoms is regarded as a crucial management factor in the most recent guidelines for the treatment of MAFLD[44-46]. The implications for public health are astounding: Semi-quantitative valvular calcium scoring, a straightforward, inexpensive, non-invasive part of a typical echocardiogram, could identify the subset of patients with fatty liver disease who have advanced to a level of systemic metabolic toxicity severe enough to calcify their heart valves[47,48]. The echocardiogram essentially becomes a dual screening tool, evaluating the structure and function of the heart while also offering a window into the degree of systemic dysregulation of the liver[49,50]. Finding significant valvular calcification should require formal hepatic risk stratification using fibrosis assessment tools (e.g., fibrosis 4, elastography), especially in younger or non-coronary patients[14].

Limitations and future directions

While the liver-driven pro-calcific phenotype is an interesting and potentially important concept[51-54], the current evidence-primarily derived from a single cross-sectional study-does not yet fully support such a definitive interpretation[1].

The study’s single-center, cross-sectional design and small sample size limit it despite its advantages. To find out if valvular calcification predicts hard outcomes like heart failure, stroke, or post-transplant mortality in cirrhosis, longitudinal studies are required[55-57]. Additionally, in order to better define the molecular processes underlying liver-valve crosstalk, future research should incorporate mechanistic approaches, combining improved imaging modalities with circulating and tissue-based biomarkers[58-60]. In the end, these initiatives might aid in determining adjustable goals and provide guidance for risk stratification tactics in this high-risk group.

CONCLUSION

Valvular calcification may be a common and aetiologically unique characteristic of LC, especially in fatty liver disease, as Vuckovic et al[1] convincingly show but further research is needed. Their results cast doubt on conventional theories of cardiovascular risk and broaden the definition of cardiohepatic disease to encompass structural valvular remodelling. Incorporating a methodical evaluation of valvular calcification into the treatment of cirrhosis may enhance risk assessment and promote more integrated hepatology–cardiology management approaches.